Press Release: Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors
- WTX-124 was shown to be clinically active and generally well-tolerated in patients who were relapsed/refractory to immune checkpoint inhibitor therapy - - Encouraging single agent clinical activity with three objective responses, including a durable confirmed complete response -
Press Release: Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors - Newscast
Thu, 10 Oct 2024 17:00:00 GMT at 8:00 am ET - WAT Company to present an update of its ongoing monotherapy and combination Phase 1/1b study of WTX-124 in advanced or metastatic solid tumors WATERTOWN, Mass., April 24, 2024 (GLOBE ...
Mon, 07 Oct 2024 05:02:00 GMT Biora Therapeutics is a clinical-stage biotech company developing ... oral delivery for better management of chronic diseases. This press release contains “forward-looking ...
Fri, 04 Oct 2024 07:19:00 GMT MiNK Therapeutics is a clinical-stage biopharmaceutical ... posted on our website and social media channels. This press release contains forward-looking statements that are made pursuant to ...
